EU GMP Certificate Received

BEXIMCO PHARMACEUTICALS LTD.

21 July, 2011

EU GMP Certificate Received

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids, today announces that it has received GMP ("Good Manufacturing Practices") accreditation from the Regulatory Authority of Austria for its oral solid (tablets and capsules) and sterile eye drop facilities at Tongi, Dhaka. The approval received from the Austrian Drug Authority will be recognized throughout the European Union (EU) by Mutual Recognition between the member countries. This is a significant milestone for the company which should facilitate exports to the lucrative generic drug markets of Europe.

"We are very pleased to reach such an important milestone with the EU approval," said Nazmul Hassan, Managing Director of Beximco Pharma. "This approval is a testimony to the high standards of quality and compliance practices put in place by the Company. This is an important step towards our aspiration to become a global generic drug player, and particularly for building our presence in the regulated markets of US and EU."

Beximco Pharma is currently exporting to many countries around the world and its state-of-the-art manufacturing facilities have already received approvals from global regulatory authorities including TGA (Australia), GCC (Gulf), ANVISA (Brazil) and INVIMA (Colombia). The Company has recently entered the US pharma market through the acquisition of an Abbreviated New Drug Application (ANDA) of a cardiovascular drug. Two products have already been filed for marketing approval in the EU, while a number of products are in the pipeline.

For further information please visit www.beximco-pharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.2080

Libertas Capital Corporate Finance

Jakob Kinde / Thilo Hoffmann

Tel: +44 (0)20 7569 9650

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.